Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Epidemiology and Applied Research Branch, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, MS S107-4, Chamblee, GA, 30341, USA.
Cancer Causes Control. 2022 Aug;33(8):1121-1124. doi: 10.1007/s10552-022-01598-3. Epub 2022 Jun 29.
Women exposed to diethylstilbestrol (DES) in utero were at elevated risk of clear-cell adenocarcinoma of the vagina and cervix (CCA) as young women. Previous research suggested that this elevated risk of CCA may persist into adulthood. We extended a published analysis to measure CCA risk as these women aged.
Standardized incidence ratios (SIR) compared CCA risk among women born from 1947 through 1971 (the DES-era) to CCA risk among the comparison group of women born prior to 1947, using registry data that covered the US population.
Incidence rates of CCA among both cohorts increased with age. Among the DES-era birth cohort, higher rates of CCA were observed across all age groups except 55-59 years. SIR estimates had wide confidence intervals that often included the null value.
Results are consistent with prior research and suggest an elevated risk of CCA in midlife and at older ages among women exposed in utero to DES. These results highlight unresolved issues regarding cancer risk among aging DES daughters and appropriate screening guidance. The examination of population-based cancer surveillance data may be a useful tool for monitoring trends in the incidence of other rare cancers over time among specific birth cohorts.
子宫内暴露于己烯雌酚(DES)的女性在年轻时患阴道透明细胞腺癌(CCA)的风险增加。先前的研究表明,这种 CCA 的风险增加可能会持续到成年期。我们扩展了一项已发表的分析,以衡量这些女性随着年龄增长的 CCA 风险。
使用涵盖美国人口的登记数据,通过比较 1947 年至 1971 年(DES 时代)出生的女性与 1947 年之前出生的对照组女性的 CCA 风险,计算标准化发病比(SIR)。
两个队列的 CCA 发病率均随年龄增长而增加。在 DES 时代出生的队列中,除了 55-59 岁年龄组外,所有年龄组的 CCA 发病率均较高。SIR 估计值的置信区间较宽,通常包括零值。
结果与先前的研究一致,表明子宫内暴露于 DES 的女性在中年和老年时 CCA 的风险增加。这些结果突出了关于 DES 女儿的癌症风险以及适当的筛查指导方面尚未解决的问题。对基于人群的癌症监测数据的检查可能是一种有用的工具,可以随着时间的推移监测特定出生队列中其他罕见癌症发病率的趋势。